Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Lenacapavir, a once-a-year injection, can treat HIV, prevent transmission and stop new infections — all with a single shot.

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

Since 2018, three medications have been approved by the FDA for use in heavily treatment-experienced or treatment-resistant HIV: ibalizumab, fostemsavir and lenacapavir.

Jacquie Ross; Senior Vice President - Treasury, Investor Relations; Gilead Sciences Inc. Daniel O'Day; Chairman, Chief Executive Officer; Gilead Sciences Inc. Johann ...